Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q12974
UPID:
TP4A2_HUMAN
Alternative names:
HU-PP-1; OV-1; PTP(CAAXII); Protein-tyrosine phosphatase 4a2; Protein-tyrosine phosphatase of regenerating liver 2
Alternative UPACC:
Q12974; A8K9I8; B4DM39; D3DPP0; E9PGJ6; O00649; Q15197; Q15259; Q15260; Q15261; R4GN50
Background:
Protein tyrosine phosphatase type IVA 2, known by alternative names such as HU-PP-1, OV-1, and PTP(CAAXII), plays a pivotal role in cell cycle progression, specifically facilitating the transition from G1 to S phase during mitosis. Its activity is characterized by the inhibition of geranylgeranyl transferase type II, impacting the association between RABGGTA and RABGGTB, which is crucial for tumor promotion.
Therapeutic significance:
Understanding the role of Protein tyrosine phosphatase type IVA 2 could open doors to potential therapeutic strategies, particularly in the realm of cancer treatment where its tumor-promoting activities are evident.